- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04764864
Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing
Randomized Multicenter Study on the Management of Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing
Pelvic fracture is a usual injury in trauma patients. An unstable trauma patient with a pelvic fracture has an elevated risk of death due to pelvic bleeding and the associated injuries. Traditionally, it has been estimated that the main source of bleeding is venous and, consequently, the main treatment has been the preperitoneal pelvic packing. Nevertheless, according to new data, arterial bleeding appears to be a more important source of pelvic bleeding than it was thought and angioembolization seems to be a good alternative in the treatment of these injuries. Consequently, it is important to define better the management of these patients.
This investigation project consists in a clinical trial study, performed by a multidisciplinary team of many hospitals around the country, in which angioembolization and preperitoneal pelvic packing are compared. Unstable trauma patients with a pelvic fracture and no other injuries (negative FAST / peritoneal aspiration, no evidence of bone fractures or thoracic injuries) will be submitted, in less than 60 minutes from hospital arrival, to angioembolization or preperitoneal pelvic packing, according to randomization. There will be a specific timing evaluation of different markers: hemodynamic (vital signs at arrival, immediately and 24 hours after treatment) and analytic (at arrival and upon entering to the Intensive Care Unit). Registered variables include: blood cell transfusions, vasoactive drug requirements, time elapsed between hospital admission and intervention, treatment duration, need of other strategies to stop pelvic bleeding, complications and mortality.
The objective of this study is to determinate if angioembolization is superior to preperitoneal pelvic packing for pelvic bleeding control in unstable trauma patients due to pelvic bleeding.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Corporacio Sanitaria Parc Tauli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Systolic blood pressure ≤ 90 mmHg
- Heart rate > 100 bpm
- Shock Index ≥ 0,8
- Pelvic fracture
- Negative FAST / peritoneal aspiration
Exclusion Criteria:
- Other causes of bleeding that require treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Angioembolization
|
Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed. In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated. The material used will vary depending on the characteristics of the injury and the availability of the materials. |
ACTIVE_COMPARATOR: Preperitoneal Pelvic Packing
|
Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified. Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect. A second intervention is required to remove the material in 24-48 hours. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pelvic bleeding control based on clinical response
Time Frame: 24 hours
|
Clinical response after the intervention
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Additional techniques
Time Frame: Through study completion, an average of 2 years
|
Need for additional techniques after the intervention to control bleeding associated with pelvic fracture
|
Through study completion, an average of 2 years
|
Post-procedure complications
Time Frame: Through study completion, an average of 2 years
|
Presence of post-procedure complications
|
Through study completion, an average of 2 years
|
Post-procedure complications degree
Time Frame: Through study completion, an average of 2 years
|
Description of post-procedure complications: Clavien Dindo scale
|
Through study completion, an average of 2 years
|
Post-procedure complications degree
Time Frame: Through study completion, an average of 2 years
|
Description of post-procedure complications: Comprehensive Complication Index
|
Through study completion, an average of 2 years
|
Mortality
Time Frame: Through study completion, an average of 2 years
|
Death of the pacient (cause and date)
|
Through study completion, an average of 2 years
|
Blood cell transfusion
Time Frame: Through study completion, an average of 2 years
|
Need for blood cell transfusion for patients (number and need for masive transfusion protocol activation)
|
Through study completion, an average of 2 years
|
Time until intervention
Time Frame: Time until intervention (up to 60 minutes)
|
Time elapsed between hospital admission and intervention
|
Time until intervention (up to 60 minutes)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time until arrival at hospital
Time Frame: Time until arrival at hospital (up to 30 minutes)
|
Time elapsed between prehospital attention and hospital admission
|
Time until arrival at hospital (up to 30 minutes)
|
Duration of angioembolization
Time Frame: Through study completion, an average of 2 years
|
Duration of angioembolization
|
Through study completion, an average of 2 years
|
Angioembolization treatment
Time Frame: Through study completion, an average of 2 years
|
Arteries treated with angioembolization
|
Through study completion, an average of 2 years
|
Duration of Preperitoneal Pelvic Packing
Time Frame: Through study completion, an average of 2 years
|
Duration of Preperitoneal Pelvic Packing
|
Through study completion, an average of 2 years
|
Intensive care unit stay
Time Frame: Through study completion, an average of 2 years
|
Number of days that the patient remains in the intensive care unit
|
Through study completion, an average of 2 years
|
Hospital stay
Time Frame: Through study completion, an average of 2 years
|
Number of days that the patient remains in hospital
|
Through study completion, an average of 2 years
|
Readmission
Time Frame: 30 days after discharge
|
Readmission 30 days after discharge
|
30 days after discharge
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Andrea Campos-Serra, MD, Corporacion Parc Tauli
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PELVITRAU
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
University Hospital, AngersRecruiting
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminatedTrauma, Multiple | Trauma Severity Indices | Injuries, Multiple | Norway/Epidemiology | Trauma Centers/Statistics & Numerical Data
-
Fundacion Clinica Valle del LiliUniversity of Pittsburgh; Hospital Universitario del Valle Evaristo GarciaRecruitingTrauma | Trauma Injury | Trauma, MultipleColombia
Clinical Trials on Angioembolization
-
University of California, IrvineTerminated
-
Methodist Health SystemRecruitingPelvic HemorrhageUnited States
-
Uppsala UniversityShandong Provincial HospitalCompletedFractures, Bone | Shock, Hemorrhagic | Multiple TraumaChina
-
McGill University Health Centre/Research Institute...ASGECompletedMALIGNANT GASTROINTESTINAL BLEEDINGCanada